Phase 1 B-cell Non Hodgkin Lymphoma Clinical Trials
23 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 23 trials
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mantle Cell LymphomaSmall Lymphocytic LymphomaB-cell Non Hodgkin Lymphoma+2 more
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Phase 1
CD45BE-HSPC + CART-45 Cells
Hodgkin LymphomaRichter's TransformationT-cell Non-Hodgkin Lymphoma+1 more
University of Pennsylvania42 enrolled1 locationNCT07451054
Recruiting
Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
B-cell Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 1
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Kansas Medical Center54 enrolled1 locationNCT06879340
Recruiting
Phase 1Phase 2
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
AstraZeneca91 enrolled22 locationsNCT07123454
Recruiting
Phase 1
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma+1 more
AstraZeneca227 enrolled27 locationsNCT04594642
Recruiting
Phase 1Phase 2
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver45 enrolled1 locationNCT04544592
Recruiting
Phase 1Phase 2
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Chronic Lymphocytic LeukemiaB-cell Non Hodgkin Lymphoma
Medical University of South Carolina27 enrolled1 locationNCT05702853
Recruiting
Phase 1
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaMantle Cell LymphomaB-cell Non Hodgkin Lymphoma+5 more
City of Hope Medical Center15 enrolled1 locationNCT05432635
Recruiting
Phase 1
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Recurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Small Lymphocytic Lymphoma+12 more
Mayo Clinic27 enrolled1 locationNCT06191887
Recruiting
Phase 1
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
Sanofi96 enrolled16 locationsNCT06392477
Recruiting
Phase 1
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University24 enrolled1 locationNCT06707259
Recruiting
Phase 1
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
B-cell Non Hodgkin Lymphoma
Tongji Hospital27 enrolled1 locationNCT07053670
Recruiting
Phase 1
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+2 more
Iksuda Therapeutics Ltd.140 enrolled13 locationsNCT05365659
Recruiting
Phase 1
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
B-cell Non Hodgkin Lymphoma
Ruijin Hospital56 enrolled1 locationNCT07072169
Recruiting
Phase 1
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.112 enrolled1 locationNCT06251180
Recruiting
Phase 1
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
Peking University Cancer Hospital & Institute42 enrolled3 locationsNCT06313957
Recruiting
Phase 1
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT05472558
Recruiting
Phase 1
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
Kai Hu24 enrolled1 locationNCT06822868